Medco Offering MolecularMD Companion Dx Test for Tyrosine Kinase Inhibitor Response | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Medco Health Solutions will offer patients diagnosed with chronic myeloid leukemia a companion diagnostic test to assess their response to tyrosine kinase inhibitor, or TKI, therapy under an agreement with MolecularMD announced today.

MolecularMD's qRT-PCR BCR-ABL assay will be used to help physicians make treatment decisions and to monitor patients on TKI therapy, under the terms of the deal.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.